Advertisement

July 22, 2019

Canon Medical's Alphenix 4D CT System Introduced in the United States

July 22, 2019—Canon Medical Systems USA, Inc. announced the introduction of its Alphenix four-dimensional (4D) CT system with the first commercial installation at West Virginia University (WVU) Heart and Vascular Institute in Morgantown, West Virginia.

According to Canon Medical, the system's innovative angiography configuration expands the capabilities in interventional procedures. The configuration pairs the Alphenix Sky + C-arm and Hybrid Catheterization Tilt/Cradle Table for interventional procedures with the company's Aquilion One/Genesis Edition CT system, allowing clinicians to efficiently plan, treat, and verify in a single clinical setting.

The WVU Heart and Vascular Institute uses the Alphenix 4D CT to perform interventional procedures for a wide range of applications, including advanced neurointerventional work and to calculate diagnoses for heart and vascular diseases. In addition, the system helps identify and treat gastrointestinal bleeds, tumor lesions, and chest hematomas, among other complications, as well as perform percutaneous embolization. The Alphenix 4D CT is part of Canon Medical’s suite of "Collaborative Imaging" tools that provide integrated imaging intelligence at the center of patient treatment. The initiative fuses multiple diagnostic imaging modalities with clinical applications to deliver holistic, optimized patient information to health care providers at the point of care, stated Canon Medical.

Luke Marone, MD, Co-Director, Chief of Vascular Interventional Services at WVU Heart and Vascular Institute, commented in the announcement, “As we looked to upgrade our interventional radiology equipment, we first had to determine what is driving healthcare and found that a large focus is on heart disease, vascular disease and cancer. Already, the system has helped our clinicians think strategically about how they can leverage new technology to expand the horizons of care we offer.”

Advertisement


July 23, 2019

Ablative Solutions Begins TARGET BP Global Clinical Trial of the Peregrine Renal Denervation System for Uncontrolled Hypertension

July 22, 2019

Meta-Analysis Shows Midterm Mortality Benefit of Statin Therapy After TAVR